At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 71 enrolled
Drug / intervention
LYR-210 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Randomized, Blinded, Sham Procedure-Controlled, Parallel-Group Trial to Evaluate the Efficacy, Safety and Tolerability of LYR-210 in Adult Subjects With Chronic Sinusitis (LANTERN Study)
In Brief
A Phase 2 clinical trial evaluating LYR-210 and Sham comparator for Chronic Sinusitis and Chronic Rhinosinusitis (Diagnosis). Completed, enrolled 71 participants across 22 sites in 5 countries.
Detailed Summary
This is a Phase II, Randomized, Blinded, Sham Procedure-Controlled, Parallel-Group Trial to Evaluate the Efficacy, Safety and Tolerability of LYR-210 in Adult Subjects with Chronic Sinusitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, Austria, Czechia, New Zealand, Poland
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
Enrollment StartMay 2019
First PostedAug 2019
Primary CompletionMar 2020
Study CompletionFeb 2021
TodayJul 2026
First PostedAug 1, 2019
Enrollment StartMay 9, 2019
Primary CompletionMar 25, 2020
Study CompletionFeb 4, 2021
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 6.9 years ago
Interventions
LYR-210drug
A single administration of LYR-210 depot
Sham comparatorother
Sham comparator